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Abstract 
Background: Cardiac syndrome X (CSX) is characterized by angina pectoris but with patent coronary arteries. Our 
previous study showed that CSX subjects had decreased serum adiponectin but higher leptin and insulin resistance 
(IR). However, few studies have investigated circulating adipokines and IR in subjects with combined metabolic syn‑
drome X (MetX) and CSX.
Methods: Fifty‑nine subjects with CSX were retrospectively enrolled from our cardiac catheterization patient 
databank. Fifty‑four subjects with valvular heart disease or arrhythmia and with normal coronary angiograms were 
recruited as the non‑CSX comparison group. The study subjects were reclassified according to the presence or 
absence of MetX. Circulating adipokines and degree of IR were measured.
Results: Subjects with combined MetX and CSX had a significantly higher HOMA‑IR, a higher circulating leptin level 
(median 8.7 vs. 3.3 ng/mL, p < 0.001), but a lower circulating adiponectin level (median 2.8 vs. 12.3 μg/mL, p < 0.001) 
than those without MetX and CSX. In pairwise comparisons, combined MetX and CSX subjects had a similar circulat‑
ing adipokines and IR index as those who had only either one syndrome X. In a multivariate regression analysis, serum 
triglycerides (odds ratio 1.011, p = 0.024) and hypertension (odds ratio 14.453, p = 0.003) were independently associ‑
ated with diagnosis of combined MetX and CSX.
Conclusions: Combined MetX and CSX had a significantly higher HOMA‑IR, a higher circulating leptin but a lower 
circulating adiponectin level than those without MetX and CSX. Combined syndrome X did not confer more changes 
on adipokines or IR index comparing with those with only one syndrome X.
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Background
Metabolic syndrome X (MetX) is a special cluster of 
atherosclerotic risk factors associated with obesity and 
insulin resistance (IR) [1]. Subjects with MetX have a 
higher incidence of cardiovascular diseases and increased 
cardiovascular mortality [2–5]. We and others have 
demonstrated that patients of MetX had decreased cir-
culating adiponectin but increased leptin and a higher 
inflammatory status [6–8].
Subjects with cardiac syndrome X (CSX) have angina 
like symptoms with evidence of ischemia in stress elec-
trocardiogram or isotope perfusion scan but with patent 
epicardial coronary arteries on coronary angiogram [9–
11]. The proposed mechanisms underlying CSX included 
endothelial dysfunction with impaired vaso-dilatory 
reserve in micro-vascular beds, inflammation, IR, estro-
gen deficiency, or oxidative stress [12, 13].
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The two syndrome Xs, CSX and MetX, shared some 
common features and pathogenesis. In one study, hyper-
insulinemia during oral glucose tolerance test was more 
prominent in the CSX group than in controls, which 
implies that IR might contribute to the micro-vascular 
angina [14]. In addition, Jadhav et  al. [15] reported that 
women with CSX more commonly had MetX and related 
adiposity, metabolic and inflammatory derangements. 
Using hyper-insulinemia and the euglycemia clamp test, 
other investigators found that subjects with CSX or MetX 
had higher degree of IR as compared to controls [16].
Several clinical studies have found decreased circu-
lating adiponectin level in populations with hyperten-
sion, obesity, MetX, type 2 DM, and coronary artery 
disease (CAD) [17–19]. Increased food intake and IR 
have been shown to increase plasma leptin levels and 
lead to leptin resistance in tissue, which is very common 
in obesity and MetX [20]. Elevated serum leptin level is 
also an independent risk factor for development of ath-
erosclerotic cardiovascular disease and MetX [21]. Our 
previous study showed that CSX subjects had lower cir-
culating adiponectin but higher leptin and higher leptin/
adiponectin ratio than those of the control group [22]. 
There was also a report showing that women with CSX 
had a higher circulating leptin than the healthy control 
group after body mass index correction [15].
To date, few studies have investigated circulating adi-
pokines and IR in subjects with double syndrome X that 
is, combined MetX and CSX, or either syndrome X alone. 
Moreover, the usefulness of the clinical variables associ-
ated with the diagnosis of combined syndrome X among 
subjects who have undergone coronary angiogram but 
without stenosis remained unexplored. The aims of the 
present study were to compare circulating adipokine 
levels in subjects with either MetX or CSX or both and 
determine what component of MetX or other atheroscle-
rotic or cytokine markers are associated with the pres-
ence of combined MetX and CSX.
Methods
Study population
From January 2010 to February 2011, a total of 2490 car-
diac catheterization procedures, including coronary angio-
grams, percutaneous coronary or peripheral vascular 
interventions, electrophysiological studies, catheter radi-
ofrequency ablations and pacemaker implantations, were 
performed at our catheterization laboratories. Among the 
patients who underwent these procedures, 830 patients 
agreed to donate a blood sample for research purposes and 
signed an informed consent form. Subjects with significant 
coronary stenosis (N = 235) (Gensini score >0 or Syntax 
score >0) [23, 24] or past histories of surgical or percutane-
ous coronary revascularization before the index admission 
(N  =  388) were excluded. After excluding 59 additional 
subjects with overt DM requiring medical control, the 
remaining 148 non-diabetic subjects with normal coro-
nary angiograms were enrolled for analysis. Among these 
148 subjects, 35 patients were excluded because of decom-
pensated congestive heart failure or without non-invasive 
tests for myocardial ischemia (Fig.  1). Fifty-nine patients 
who had chest pain with clinical suspicion of angina pec-
toris and had undergone non-invasive tests suggesting 
myocardial ischemia were defined as having CSX, while 
54 patients with valvular heart disease or arrhythmia who 
underwent coronary angiograms for pre-operative or peri-
procedural study without mention of chest pain were clas-
sified as the non-CSX group for comparisons (Fig. 1) [22]. 
Some of the study results have been published previously 
[22]. The 59 CSX and 54 non-CSX subjects were subse-
quently regrouped according to the presence or absence of 
MetX (Fig. 1). The definition of MetX was made according 
to the ATP III criteria [25], with modification of the central 
obesity criterion into body mass index (BMI) equal to or 
greater than 27 kg/m2 [26]. Those who did not have MetX 
or CSX served as the control group. We retrospectively 
reviewed all patients’ angiographic images, catheterization 
reports, and medical chart records. The study protocol was 
approved by the Human Research Review Committee of 
Taichung Veterans General Hospital (Taichung, Taiwan).
High‑sensitivity C‑reactive protein (hs‑CRP), fasting 
blood glucose, insulin, and the definition of HOMA 
insulin‑resistance index
Serum high-sensitivity C-reactive protein (hs-CRP) was 
determined by particle-enhanced immunoturbidim-
etry (Good Biotech Corp., Taichung, Taiwan) [8]. The 
intra- and inter-assay coefficients of variance were 0.75 
and 1.89  %, respectively. The calculated low-density 
Fig. 1 Flow chart of the study enrollment protocol. CAG coronary 
angiogram, CHF congestive heart failure, DM diabetes mellitus, CSX 
cardiac syndrome X, MetX metabolic syndrome X
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lipoprotein (LDL) cholesterol concentration was esti-
mated by the formula devised by Friedewald et  al. [27]. 
Serum insulin was determined using a commercially 
available assay kit (IMMULITE, I-2000, EURO/Diag-
nostic Products Corporation, Gwynedd, UK) [28]. The 
inter- and intra-assay coefficients of variation for insulin 
(range 10.7–439 μU/mL) were 4.3 and 5.4 %, respectively. 
Homeostasis model assessment (HOMA) index was cal-
culated (fasting glucose mg/dL  ×  fasting insulin μU/
mL/405) as an index of IR.
Measurements of circulating serum adipokines
Serum adiponectin and leptin levels were determined by 
the enzyme-linked immunosorbent assay (ELISA) kits (R 
& D Systems Inc. Minneapolis, MN, USA). The intra- and 
inter-assay coefficients of variation for adiponectin were 
3.53 and 6.50  %, respectively, with a minimum detect-
able concentration of 0.079–0.891 ng/mL. The intra- and 
inter-assay coefficients of variation for leptin were 3.17 
and 4.37 %, respectively, with a minimum detectable con-
centration of lower than 7.8 pg/mL.
Statistical analysis
Continuous variables are expressed as median (inter-
quartile range, 25th percentile to 75th percentile) 
because of a non-normal distribution and categorical 
data are expressed as percentages. Differences in con-
tinuous variables among the CSX, MetX, combined CSX 
and MetX and control groups were assessed by the 
Kruskal–Wallis test. The post hoc pairwise compari-
sons were analyzed by the Mann–Whitney U test (with 
a Bonferroni correction, p cut-off value for significance 
<0.0083). Categorical variables were compared by Chi 
square test or Fisher’s exact test as indicated. Binary 
logistic regression analyses were used to test significant 
variables associated with the diagnosis of “combined 
CSX and MetX”, “CSX without MetX” or “MetX with-
out CSX”. The SPSS (version, 12.1) statistical software 
package (SPSS, Inc., Chicago, IL, USA) was used for all 
calculations. A two-tailed p value of less than 0.05 was 
considered statistically significant.
Results
Baseline demographic data, inflammatory marker and lipid 
profiles in subjects with and without cardiac or metabolic 
syndrome X
The gender and age were similar among the four groups 
(Table  1). Subjects with combined syndrome X had a 
greater BMI than the control (p < 0.001). The inflamma-
tory marker, hs-CRP, was similar among the four groups 
(Table  1). Total cholesterol and triglycerides were sig-
nificantly different among the four groups and were 
Table 1 Baseline demographic data of subjects with and without cardiac or metabolic syndrome X
Data are expressed as median (interquartile range, 25th percentile to 75th percentile) because of a non-normal distribution
ACEI angiotensin converting enzyme inhibitors, ARB angiotensin receptor blockers, CSX cardiac syndrome X, HDL-C high-density lipoprotein cholesterol, Hs-CRP high 
sensitivity C-reactive protein, LDL-C low-density lipoprotein cholesterol, MetX metabolic syndrome X, Statin HMG-CoA reductase inhibitors
a p value for Kruskal–Wallis test among the four groups
b p value Mann–Whitney U test for CSX (+) and MetX (+) vs. CSX (−) and MetX (−)














Gender (M/F) 25/14 25/10 8/7 14/10 0.593
Age (years) 59 (49, 68) 56 (50, 65) 54 (46, 61) 55 (50, 66) 0.638 0.655
Hypertension (N) (%) 8 (20.5 %) 15 (42.9 %) 9 (60 %) 22 (91.7 %) <0.001
Body mass index (kg/m2) 23.8 (22.4, 26.0) 25.2 (23.9, 27.6) 28.6 (25.5, 31.5) 27.7 (24.6, 30.8) <0.001 <0.001
Current smoking (N) (%) 2 (5.1 %) 6 (17.1 %) 4 (26.7 %) 9 (37.5 %) 0.012
Total cholesterol (mg/dL) 151 (134, 170) 164 (146, 193) 166 (135, 196) 185 (159, 211) 0.004 <0.001
Calculated LDL‑C (mg/dL) 83 (74, 104) 96 (83, 120) 93 (67, 106) 97 (76, 134) 0.105 0.057
HDL‑C (mg/dL) 48 (41, 60) 51 (46, 56) 42 (36, 44) 43 (38, 48) <0.001 0.015
Triglycerides (mg/dL) 86 (51, 115) 83 (64, 113) 156 (116, 192) 203 (145, 240) <0.001 <0.001
Fasting plasma glucose (mg/dL) 94 (88, 112) 95 (89, 113) 110 (102, 126) 106 (93, 128) 0.012 0.015
Fasting serum insulin (µIU/mL) 4.5 (2.9, 9.9) 8.4 (4.9, 10.6) 9.2 (5.9, 16.7) 9.4 (5.1, 19.9) 0.022 0.012
Hs‑CRP (mg/dL) 0.127 (0.057, 0.344) 0.079 (0.036, 0.297) 0.220 (0.152, 0.530) 0.138 (0.082, 0.318) 0.180 0.661
Medication use
 Use of statin (N) (%) 3 (7.7 %) 2 (5.7 %) 0 3 (12.5 %) 0.506
 Use of ACEI or ARB (N) (%) 12 (30.8 %) 7 (20 %) 3 (20 %) 10 (41.7 %) 0.270
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significantly higher in subjects with combined MetX 
and CSX (p  <  0.001 vs. without MetX and CSX group) 
(Table 1).
Circulating adipokine levels and insulin‑resistance 
index in subjects with and without cardiac or metabolic 
syndrome X
Circulating adiponectin and leptin were significantly 
different among the four groups (p  <  0.001) (Table  2). 
Subjects with combined MetX and CSX had a lower cir-
culating adiponectin level (median 2.8 vs. 12.3 μg/mL, 
p < 0.001) than those without MetX and CSX (Table 2). 
In pairwise comparisons, subjects with CSX alone 
(median 3.4 μg/mL, p  <  0.001) or MetX alone (median 
4.0 μg/mL, p = 0.002) also had a significantly lower adi-
ponectin level than the control group (median 12.3 μg/
mL) (Table 2). In terms of circulating leptin, subjects with 
combined MetX and CSX (median 8.7 ng/mL, p < 0.001) 
or MetX alone (median 8.1 ng/mL, p = 0.002) had a sig-
nificantly higher leptin than the control group (median 
3.3  ng/mL) (Table  2). The HOMA-IR was significantly 
different among the four groups (p = 0.009), and subjects 
with combined MetX and CSX had a significantly higher 
HOMA-IR than the control (p = 0.005) (Table 2). Moreo-
ver, combined MetX and CSX subjects had a similar cir-
culating adiponectin, leptin and IR index comparing with 
those who had only either one syndrome X (Table 2).
Binary logistic regression analysis of variables associated 
with the diagnosis of “combined cardiac and metabolic 
syndrome X (double syndrome X)”
In the analysis, which included five components of 
MetX, cigarette smoking status, IR index, circulating adi-
pokines, age and gender, hypertension (odds ratio 14.453, 
Table 2 Circulating adipokine levels and insulin-resistance index in subjects with and without cardiac or metabolic syn-
drome X
Data are expressed as median (interquartile range, 25th percentile to 75th percentile) because of a non-normal distribution
CSX cardiac syndrome X, MetX metabolic syndrome X, HOMA-IR homeostasis model assessment (HOMA) index of insulin resistance = (fasting glucose mg/dL × fasting 
insulin μU/mL)/405
Mann–Whitney U test for comparisons below (Bonferroni corrected p cut-off value for significance <0.0083)
Adiponectin
Adiponectin CSX(−) MetX (−) vs. CSX (+) MetX (+), p < 0.001
Adiponectin CSX(−) MetX (−) vs. CSX (+) MetX (−), p < 0.001
Adiponectin CSX (−) MetX (−) vs. CSX (−) MetX (+), p = 0.002
Adiponectin CSX (+) MetX (−) vs. CSX (+) MetX (+), p = 0.260
Adiponectin CSX (−) MetX (+) vs. CSX (+) MetX (+), p = 0.326
Adiponectin CSX (−) MetX (+) vs. CSX (+) MetX (−), p = 0.924
Leptin
Leptin CSX(−) MetX (−) vs. CSX (+) MetX (+), p < 0.001
Leptin CSX(−) MetX (−) vs. CSX (+) MetX (−), p = 0.067
Leptin CSX (−) MetX (−) vs. CSX (−) MetX (+), p = 0.002
Leptin CSX (+) MetX (−) vs. CSX (+) MetX (+), p = 0.030
Leptin CSX (−) MetX (+) vs. CSX (+) MetX (+), p = 0.603
Leptin CSX (−) MetX (+) vs. CSX (+) MetX (−), p = 0.105
HOMA-IR
HOMA-IR CSX(−) MetX (−) vs. CSX (+) MetX (+), p = 0.005
HOMA-IR CSX(−) MetX (−) vs. CSX (+) MetX (−), p = 0.023
HOMA-IR CSX (−) MetX (−) vs. CSX (−) MetX (+), p = 0.044
HOMA-IR CSX (+) MetX (−) vs. CSX (+) MetX (+), p = 0.151
HOMA-IR CSX (−) MetX (+) vs. CSX (+) MetX (+), p = 0.862
HOMA-IR CSX (−) MetX (+) vs. CSX (+) MetX (−), p = 0.130
a p value for Kruskal–Wallis test among the four groups














Adiponectin (μg/mL) 12.3 (7.0, 18.9) 3.4 (2.3, 7.2) 4.0 (2.0, 9.1) 2.8 (1.7, 7.7) <0.001 <0.001
Leptin (ng/mL) 3.3 (1.3, 8.1) 5.1 (3.1, 11.0) 8.1 (5.1, 18.5) 8.7 (6.3, 17.4) <0.001 <0.001
HOMA‑IR 1.04 (0.72, 2.47) 1.93 (1.28, 2.62) 2.40 (1.78, 4.21) 2.23 (1.48, 5.89) 0.009 0.005
Page 5 of 8Liang et al. Diabetol Metab Syndr  (2015) 7:83 
p = 0.003) and triglycerides (odds ratio 1.011, p = 0.024) 
were positively associated with the presence of combined 
CSX and MetX (Table 3).
Binary logistic regression analysis of variables associated 
with the diagnosis of “CSX without MetX”
Using “CSX without MetX” as the dependent variable, we 
found that higher serum triglycerides (odds ratio 0.979, 
p = 0.001) and higher circulating adiponectin (odds ratio 
0.876, p  =  0.002) were negatively associated with the 
diagnosis of “CSX without MetX” (Table 4).
Binary logistic regression analysis of variables associated 
with the diagnosis of “MetX without CSX”
Using “MetX without CSX” as the dependent variable, 
we found that BMI was positively correlated (odds ratio 
1.529, p = 0.006), while higher HDL-C (odds ratio 0.915, 
p = 0.049) and male gender (odds ratio 0.118, p = 0.037) 
were negatively associated with the diagnosis of “MetX 
without CSX” (Table 5).
Discussion
The main finding of our study was that subjects with 
combined MetX and CSX had a significantly higher 
HOMA-IR, a higher circulating leptin, but a lower cir-
culating adiponectin level than those without MetX 
and CSX. Combined syndrome X did not confer more 
changes on adipokines or IR index comparing with those 
with only one syndrome X. Serum triglycerides and 
hypertension were independently associated with the 
Table 3 Binary logistic regression analysis of independent 
variables associated with  “combined cardiac and  meta-
bolic syndrome X”
Dependent variable: “combined cardiac and metabolic syndrome X”
Independent variables: components of metabolic syndrome, adipokines, insulin-
resistance index, smoking status, age, gender
CI confidence interval, HDL-C high-density lipoprotein cholesterol, HOMA-IR 
homeostasis model assessment (HOMA) index of insulin-resistance = (fasting 
glucose mg/dL × fasting insulin μU/mL)/405, OR odds ratio





Hypertension (with vs. 
without)
0.003 14.453 2.491 83.868
Body mass index (kg/m2) 0.593 1.055 0.866 1.286
Fasting glucose (mg/dL) 0.291 1.014 0.989 1.039
HDL‑C (mg/dL) 0.200 0.949 0.876 1.028
Triglycerides (mg/dL) 0.024 1.011 1.001 1.021
Current smoking (yes vs. 
no)
0.069 4.969 0.883 27.974
HOMA‑IR 0.881 0.981 0.763 1.261
Leptin (ng/mL) 0.758 1.007 0.965 1.050
Adiponectin (μg/mL) 0.638 0.978 0.893 1.072
Age (years) 0.491 1.025 0.955 1.100
Gender (male vs. female) 0.226 0.320 0.051 2.021
Table 4 Binary logistic regression analysis of  independ-
ent variables associated with  “cardiac syndrome X with-
out metabolic syndrome X”
Dependent variable: “cardiac syndrome X without metabolic syndrome X”
Independent variables: components of metabolic syndrome, adipokines, insulin-
resistance index, smoking status, age, gender
CI confidence interval, HDL-C high-density lipoprotein cholesterol, HOMA-IR 
homeostasis model assessment (HOMA) index of insulin-resistance = (fasting 
glucose mg/dL × fasting insulin μU/mL)/405, OR odds ratio





Hypertension (with vs. 
without)
0.726 0.821 0.273 2.470
Body mass index (kg/m2) 0.443 0.941 0.807 1.098
Fasting glucose (mg/dL) 0.931 0.999 0.981 1.018
HDL‑C (mg/dL) 0.284 1.026 0.979 1.076
Triglycerides (mg/dL) 0.001 0.979 0.967 0.991
Current smoking (yes vs. 
no)
0.842 0.862 0.201 3.699
HOMA‑IR 0.349 0.868 0.645 1.168
Leptin (ng/mL) 0.137 1.033 0.990 1.079
Adiponectin (μg/mL) 0.002 0.876 0.807 0.951
Age (years) 0.384 1.023 0.972 1.077
Gender (male vs. female) 0.261 2.108 0.575 7.731
Table 5 Binary logistic regression analysis of  independ-
ent variables associated with “metabolic syndrome X with-
out cardiac syndrome X”
Dependent variable: “metabolic syndrome X without cardiac syndrome X”
Independent variables: components of metabolic syndrome, adipokines, insulin-
resistance index, smoking status, age, gender
CI confidence interval, HDL-C high-density lipoprotein cholesterol; HOMA-IR: 
homeostasis model assessment (HOMA) index of insulin-resistance = (fasting 
glucose mg/dL × fasting insulin μU/mL)/405, OR odds ratio





Hypertension (with vs. 
without)
0.702 0.749 0.171 3.285
Body mass index (kg/m2) 0.006 1.529 1.131 2.066
Fasting glucose (mg/dL) 0.240 1.014 0.991 1.037
HDL‑C (mg/dL) 0.049 0.915 0.838 1.000
Triglycerides (mg/dL) 0.116 1.008 0.998 1.019
Current smoking (yes vs. 
no)
0.605 0.580 0.073 4.578
HOMA‑IR 0.304 0.866 0.658 1.139
Leptin (ng/mL) 0.089 0.928 0.852 1.011
Adiponectin (μg/mL) 0.743 0.984 0.896 1.081
Age (years) 0.879 0.994 0.918 1.076
Gender (male vs. female) 0.037 0.118 0.016 0.881
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diagnosis of combined MetX and CSX in subjects who 
underwent CAG but without stenosis.
Only a few small-scale studies have investigated com-
mon etiologies in CSX and MetX, which bore similar 
names of syndrome X. The most common observation 
was the presence of IR in both of these syndromes [14, 
16]. Our study found that insulin-resistance index was 
significantly higher in subjects with combined double 
syndrome X than the control group (Table 2), which fur-
ther corroborated that IR contributed to the pathogenesis 
of both CSX and MetX. However, combined syndrome X 
did not result in more changes on IR index comparing 
with those with only one syndrome X (Table 2).
There have been very few reports about the circulat-
ing adipokines in combined MetX and CSX subjects. 
Our group previously reported that subjects with CSX 
had a significantly lower serum adiponectin than those 
of the control group [22]. Subjects with MetX also had 
decreased circulating adiponectin [17, 19]. The present 
study extended the investigation into combined MetX 
and CSX and revealed a similar lower expression of adi-
ponectin in combined syndrome X as well as in MetX 
or CSX alone groups (Table 2). Previous study by Eroglu 
et al. [29] showed adiponectin levels were lower in female 
patients with normal coronary angiograms but impaired 
coronary flow reserve than those with normal reserve. 
In addition, adiponectin levels correlated with coronary 
flow reserve [29]. Their findings along with our observa-
tions [22] indicated the potential role of adiponectin in 
mediating coronary flow and microvascular dysfunction 
in CSX subjects. Leptin expression was higher in sub-
jects with CSX as reported by our research group [22] 
and others [15]. A number of studies have revealed that 
increased plasma leptin concentration is correlated with 
higher blood pressure [30], higher cholesterol level, and 
morbid obesity [19]. High levels of leptin are believed to 
be associated with lower arterial distensibility, an index 
of circulatory function relevant to the atherosclerotic 
process [31]. As leptin was correlated with several con-
ventional atherosclerotic risk factors as well as arterial 
distensibility, it is reasonable that subjects with combined 
CSX and MetX had a higher leptin expression (Table 2). 
Our study also disclosed that combined syndrome X did 
not contribute to more changes on adipokines comparing 
with those with only one syndrome X (Table 2).
A novel finding of this study is that hypertension and 
serum triglycerides were independent variables asso-
ciated with the diagnosis of combined CSX and MetX 
(Table 3). Hypertension and hypertriglyceridemia per se 
are components of MetX. Hypertriglyceridemia was a 
reflection of IR and decreased adipose tissue lipoprotein 
lipase activity [32]. CSX subjects were also characterized 
by the presence of IR and related adiposity [14, 16]. 
Hypertension and associated left ventricular hypertrophy 
impaired endothelium-mediated relaxation in human 
coronary resistance vessels [33–35]. Our previous study 
disclosed that hypertension is a significant predictor for 
the diagnosis of CSX [22]. In this study, there were sig-
nificant trends toward higher triglycerides and higher 
percentage of associated hypertension in the order of 
control, CSX, MetX and combined double syndrome X 
(Table 1). In contrast, IR index and circulating adipokines 
were similar among subjects with CSX, MetX or com-
bined double syndrome X (Table 2). Triglycerides levels 
and hypertension showed trends toward higher value and 
association in those with combined double syndrome 
X (Tables 1, 3). It may imply that decreased lipoprotein 
lipase activity, endothelium dysfunction or sympathetic 
over-activity contribute to combined double syndrome 
X [32, 35, 36]. However, the finding demands further 
in vitro and in vivo mechanism investigation.
In addition, our study also disclosed that higher serum 
triglycerides and higher circulating adiponectin were 
negatively associated with the diagnosis of “CSX without 
MetX” (Table  4). It would implicate that CSX is closely 
associated with low adiponectin related endothelium 
dysfunction and MetX is strongly related with decreased 
lipoprotein lipase activity related high triglycerides [1, 22, 
29]. Moreover, we found that higher BMI was positively 
correlated while higher HDL-C and male gender were 
negatively associated with the diagnosis of “MetX with-
out CSX” (Table  5). This would imply BMI and HDL-C 
are useful differential factors between MetX and CSX.
There are several limitations of this study. This was 
a retrospective analysis from a specific time-frame of 
the cardiac catheterization data bank in a single medi-
cal center, thus the recruited patient number and study 
power could not be specified beforehand. According to 
the data of circulating adiponectin of CSX, MetX, and 
the controls from the publications [19, 22], we think this 
retrospective analysis could have a study power around 
0.75–0.8. Moreover, this was an observational analy-
sis study without further investigation of the disease 
mechanism.
In conclusion, subjects with combined MetX and CSX 
had a significantly higher HOMA-IR, a higher circulat-
ing leptin, but a lower circulating adiponectin level than 
those without MetX and CSX. Combined MetX and CSX 
did not confer more changes on adipokines or IR index 
comparing with those with only one syndrome X. Serum 
triglycerides and hypertension were independently 
associated with the diagnosis of combined MetX and 
CSX among subjects who underwent CAG but without 
stenosis.
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